A decade of RNAi screening: Too much hay and very few needles

Drug Discovery World

Volumn 14, Issue 3, 2013, Pages 31-41

  Bhinder, Bhavneet ^a   Djaballah, Hakim ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; GENE FUNCTION; GENE TARGETING; HIGH THROUGHPUT SCREENING; RNA ANALYSIS; SCREENING TEST;

EID: 84880868817     PISSN: 14694344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Guo, S and Kemphues, KJ. par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell 81, 611-20 (1995).
2. Mohr, S et al. Genomic screening with RNAi: results and challenges. Annu Rev Biochem 79, 37-64 (2010).
3. Jackson, AL and Linsley, PS. Recognizing and avoiding siRNA OTEs for target identification and therapeutic application. Nat Rev Drug Discov 9, 57-67 (2010).
4. Sigoillot, FD and King, RW. Vigilance and validation: Keys to success in RNAi screening. ACS Chem Biol 6, 47-60 (2011).
5. Mattick, JS. Non-coding RNAs:the architects of eukaryotic complexity. EMBO reports 2, 986-91 (2001).
6. Burge, SW et al. Rfam 11.0: 10 years of RNA families. Nucleic Acids Res 41, D226-32 (2013).
7. Friedman, RC et al. Most mammalian mRNAs are conserved targets of MicroRNAs. Genome Res 19, 92-105 (2009).
8. Batista, PJ and Chang, HY. Long noncoding RNAs: cellular address codes in development and disease. Cell 152, 1298-307 (2013).
9. International Human Genome Sequencing Consortium. Finishing the Euchromatic Sequence of the Human Genome. Nature 431, 931-45 (2004).
10. Pennisi, E. Gene Counters Struggle to Get the Right Answer. Science 301, 1040-1 (2003).
11. Lord, CJ et al. RNA interference screening demystified. J Clin Pathol 62, 195-200 (2009).
12. Falschlehner, C et al. High-throughput RNAi screening to dissect cellular pathways: a how-to guide. Biotechnol J 5, 368-76 (2010).
13. Hong-Geller, E and Micheva-Viteva, SN. Functional gene discovery using RNA interference-based genomic screens to combat pathogen infection. Curr Drug Discov Technol 7, 86-94 (2010).
14. Quon, K and Kassner, PD. RNA interference screening for the discovery of oncology targets. Expert Opin Ther Targets 13, 1027-35 (2009).
15. Mizuarai, S and Kotani, H. Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements. Hum Genet 128, 567-75 (2010).
16. Swanton, C et al. Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med 2, 53 (2010).
17. Wang, XZ and Weaver, DT. The ups and downs of DNA repair biomarkers for PARP inhibitor therapies. Am J Cancer Res 1, 301-27 (2011).
18. Alberts, B et al. Studying Gene Expression and Function. Molecular Biology of the Cell 4th edition. Garland Science, New York (2002).
19. Goldsmith, ZG and Dhanasekaran, N. The microrevolution: applications and impacts of microarray technology on molecular biology and medicine (review). Int J Mol Med 13, 483-95 (2004).
20. Bhinder, B and Djaballah, H. A Simple Method for Analyzing Actives in Random RNAi Screens: Introducing the "H Score" for Gene Nomination &Prioritization. Comb Chem High Throughput Screen 15, 686-704 (2012).
21. Brass, AL et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 319, 921-6 (2008).
22. König, R et al. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135, 49-60 (2008).
23. Zhou, H et al. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 4, 495-504 (2008).
24. Bushman, FD et al. Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog 5, e1000437 (2009).
25. Pache, L et al. Identifying HIV-1 host cell factors by genome-scale RNAi screening. Methods 53, 3-12 (2011).
26. Brass. AL et al. The IFITM proteins mediate cellular resistance to influenza A HINI virus, West Nile virus, and dengue virus. Cell 139, 1243-54 (2009).
27. Luo. JL et al. Genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835-48 (2009).
28. Bhinder, B et al. An arrayed genome-scale lentiviralenabled short hairpin RNA screen identifies lethal and rescuer gene candidates. Assay Drug Dev Technol 11, 173-90 (2013).
29. Cheung, HW et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineagespecific dependencies in ovarian cancer. Proc Natl Acad Sci USA 108, 12372-77 (2011).
30. Scholl, C et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821-34 (2009).
31. Barbie, DA et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers requireTBKI. Nature 462, 108-12 (2009).
32. Naik, G. Scientists' Elusive Goal: Reproducing Study Results. WSJ.online.wsj.com (2011).
33. Babij, C et al. STK33 kinase activity is non-essential in KRAS-dependent cancer cells. Cancer Res 71, 5818-26 (2011).
34. Luo, T et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U SA 109, 2860-5 (2012).
35. Vangamudi, B et al. Evaluation of TBKI as a novel cancer target in the K-Ras pathway. Cancer Res 72, Abstract nr 1813 (2012).
36. Watt, SA et al. Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLKI and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma. Oncogene 30, 4666-77 (2011).
37. Ding. Y et al. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLKI and other therapeutic kinase targets. Cancer Res 71, 5225-34 (2011).
38. Duan, Z et al. Lentiviral shRNA screen of human kinases identifies PLK I as a potential therapeutic target for osteosarcoma. Cancer Lett 293, 220-9 (2010).
39. Hu, K et al. Small interfering RNA library screen identified polo-like kinase-1 (PLKI) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. Breast Cancer Res 14, R22 (2012).
40. Wolf, G et al. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract 196, 753-9 (2000).
41. Takahashi. T et al. Polo-like kinase I (PLKI) is overexpressed in primary colorectal cancers. Cancer Sci 94, 148-52 (2003).
42. Tokumitsu. Y et al. Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int J Oncol 15, 687-92 (1999).
43. Sarthy. AV et al. Survivin depletion preferentially reduces the survival of activated KO-Ras-transformed cells. Mol Cancer Ther 6, 269-76 (2007).
44. Zheng, M et al. Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer Res 68, 7570-8 (2008).
45. Cole, KA et al. RNAi screen of the protein kinome identifies checkpoint kinase I (CHKI) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci USA 108, 3336-41 (2011).
46. Ngo. VN et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441, 106-10 (2006).
47. Dong, G et al. A20, ABIN-1/2, and CARD I I mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma. Clin Cancer Res 17, 1440-51 (2011).
48. Bailey, CC et al. Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog 8, e 1002909 (2012).
49. Yeung, ML et al. A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-I replication. j Biol Chem 284, 19463-73 (2009).
50. Rato, S et al. Novel HIV-I knockdown targets identified by an enriched kinases/phosphatases shRNA library using a long-term iterative screen in Jurkat T-cells. PLoS One 5, e9276 (2010).
51. Lu, J et al. The IFITM proteins inhibit HIV-I infection. J Virol 85, 2126-37 (2011).
52. Bhinder, B and Djaballah, H. Systematic analysis of RNAi reports finds zero gene commonality & reveal an unprecedented enrichment in pooled screens: does depletion warrant essentiality? Assay Drug Dev Technol (2013) (under review).
53. Schlabach, MR et al. Cancer proliferation gene discovery through functional genomics. Science 319, 620-4 (2008).
54. Schultz, N et al. Off-target effects dominate a largescale RNAi screen for modulators of the TGF-ß pathway and reveal microRNA regulation of TGFBR2. Silence 2, 3 (2011).
55. Djaballah, H. Editorial: Random RNAi Screening Data Analysis: A Call for Standardization. Comb. Chem. High Throughput Screen 15, 685 (2012).
56. Kaelin Jr, WG. Use and Abuse of RNAi to study Mammalian Gene Function. Science 337, 421-2 (2012).
57. Zuber. J et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-8 (2011).
58. Berns, K et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428, 431-7 (2004).
59. Moffat, J et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124, 1283-98 (2006).
60. Chang, K et al. Lessons from nature: microRNA-based shRNA libraries. Nat Methods 3, 707-14 (2006).
61. Gu, S et al. The loop position of shRNAs and premiRNAs is critical for the accuracy of dicer processing in vivo. Cell 151, 900-11 (2012).
62. Park. JE et al. Dicer recognizes the 5' end of RNA for efficient and accurate processing. Nature 475, 201-5 (2011).
63. Vermeulen. A et al. The contributions of dsRNA structure to Dicer specificity and efficiency. RNA 11, 674-82 (2005).
64. Boettcher, M and Hoheisel. JD. Pooled RNAi Screens-Technical and Biological Aspects. Curr Genomics 11, 162-7 (2010).
65. Sims, D et al. High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing. Genome Biol 12, R104 (2011).
66. Kobayashi, N. Tamura, K and Aotsuka T. PCR error and molecular population genetics. Biochem Genet 37, 317-21 (1999).
67. Lipardi, C and Paterson, BM. Retraction for Lipardi and Paterson. Identification of an RNA-dependent RNA polymerase in Drosophila involved in RNAi and transposon suppression. Proc Natl Acad Sci U S A 108, 15010 (2011).
68. Zhang, S et al. Retracted manuscript: Overexpression of transketolase protein TKTLI is associated with occurrence and progression in nasopharyngeal carcinoma. Cancer Biol Ther 10, 110 (2010).
69. Department Of Health And Human Services: Findings of Scientific Misconduct. www.gpo.gov/fdsys/pkg/FR-2010-08-25/html/2010-21048.htm (accessed May 16, 2013).
70. Dolgin, E. Iowa biologist falsified figures. The Scientist, www.the-scientist.com (2008).
71. Ledford, H. Drug giants turn their backs on RNA interference. Nature 468, 487 (2010).
72. Banerji. V et al. The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. J Clin Invest 122, 935-47 (2012).
73. Ebert, BL et al. Identification of RPSI4 as a 5qsyndrome gene by RNA interference screen. Nature 451, 335-9 (2008).
74. Czibere. A et al. Low RPSI4 expression is common in myelodysplastic syndromes without 5q-aberration and defines a subgroup of patients with prolonged survival. Haematologica 94, 1453-5 (2009).
75. Herrmann, H et al. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stemand progenitor cells in acute myeloid leukemia AML. Oncotarget 3, 1588-99 (2012).
76. Gobeil, S et al. A genome-wide shRNA screen identifies GAS I as a novel melanoma metastasis suppressor gene. Genes Dev 22, 2932-40 (2008).
77. Wajapeyee, N et al. Oncogenic BRAF induces senescence and apoptosis through pathways mediated b) the secreted protein IGFBP7. Cell 132, 363-74 (2008).
78. Scurr, LL et al. IGFBP7 is not required for B-RAF-induced melanocyte senescence. Cell 141, 717-27 (2010)
79. Schrama, D et al. Lack of correlation between IGFBP7 expression and BRAF mutational status in melanoma. J Invest Dermatol 130, 897-8 (2010).
80. Boehm, JS et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129, 1065-79 (2007).
81. Holzel, M et al. NFI is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 142, 218-29 (2010).
82. Kolfschoten, IG et al. A genetic screen identifies PITXI as a suppressor of RAS activity and tumorigenicity. Cell 121, 849-58 (2005).
83. Westbrook, TF et al. A genetic screen for candidate tumor suppressors identifies REST. Cell 121, 837-48 (2005).
84. Eichhorn, PJ et al. USPI5 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nat Med 18, 429-35 (2012).
85. Porter, CC et al. Integrated genomic analyses identify WEE I as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia 26, 1266-76 (2012).
86. Vicent, S et al. Wilms tumor I (WTI) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest 120, 3940-52 (2010).
87. Geiger, R et al. BAP31 and BiP are essential for dislocation of SV40 from the endoplasmic reticulum to the cytosol. Nat Cell Biol 13, 1305-14 (2011).
88. Krishnan, MN et al. RNA interference screen for human genes associated with West Nile virus infection. Nature 455, 242-5 (2008).
89. Fernandez-Garcia, MD et al. Appraising the roles of CBLLI and the ubiquitin/proteasome system for flavivirus entry and replication. J Virol 85, 2980-9 (2011).
90. Swanton, C et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11, 498-512 (2007).
91. Lupberger. J et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 17, 589-95 (2011).
92. Giamas, G et al. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med 17, 715-9 (2011).
93. Stebbing. J et al. LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Res Treat 132, 537-44 (2012).
94. Bajrami, I et al. Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. EMBO Mol Med 4, 1087-96 (2012).
95. Santidrian. AF et al. Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression. J Clin Invest 123, 1068-81 (2013).
96. Morgan-Lappe, SE et al. Identification of Ras-related nuclear protein, targeting protein for xenopus kinesinlike protein 2, and stearoyl-CoA desaturase I as promising cancer targets from an RNAi-based screen. Cancer Res 67, 4390-8 (2007).
97. Zhang, H et al. Scd l Plays a Tumor-Suppressive Role in Survival of Leukemia Stem Cells and the Development of Chronic Myeloid Leukemia. Mol Cell Biol 32, 1776-87 (2012).
98. Aguirre-Portolés, C et al. Tpx2 controls spindle integrity, genome stability, and tumor development. Cancer Res 72, 1518-28 (2012).
99. Szász. AM et al. The CIN4 chromosomal instability qPCR classifier defines tumor aneuploidy and stratifies outcome in grade 2 breast cancer. PLoS One 8, e56707 (2013).